Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Google Scholar citation report
Citations : 3314

Journal of Biotechnology & Biomaterials received 3314 citations as per Google Scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • ResearchBible
  • China National Knowledge Infrastructure (CNKI)
  • Access to Global Online Research in Agriculture (AGORA)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • ICMJE
Recommended Journals
Share This Page

Investigating S100A4 as therapeutic target vis-a-vis employability of Ayurvedic concepts for advanced research and clinical relevance

6th World Congress on Biotechnology

Vivek Sharma1, Rakesh K Pandit1, Navpreet Kaur1, Shikha1, Piyusha Sharma2 and Aniket Sinha2

1Chandigarh Group of Colleges, India 2Anvaya Biosciences, India

ScientificTracks Abstracts: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.043

Abstract
S100A4 is a Ca2+ binding protein, associated with metastasis in many forms of cancer and has also been identified as a diagnostic and prognostic marker in breast cancer metastasis. In the past years scientists have shown that S100A4 binds with both intracellular and extracellular secondary protein partners to mediate the processes like EMT leading to motility and invasion, cell death and angiogenesis. This gave us a background that S100A4 can be employed as a therapeutic target for metastasis. We screened some novel compounds using Autodock4 which showed that they interact with the active site of S100A4 and have the potential to restrict its binding with secondary protein partners. The simulation studies were done using GROMACS to look at finer details of the interactions. While looking at these details which will lead to development of targeted therapies with an individualized approach, we wondered about the biological relevance of these structural interactions and possibility of translating this into an effective therapy. On the other hand approaches like Ayurveda have reports and evidences which redefine the fundamental biological principles in complete holistic sense and have the potential to open investigations for personalized and integrative medicine for even the most complicated diseases to understand, such as cancer metastasis. We in our lab and at Anvaya Biosciences are focused on developing an amalgamated platform where we can employ concepts of Tridosha, Saptdhatu and Panchmahabhutas together with tools of genomics and proteomics to come up with integrative therapies which can be employed clinically.
Biography

Vivek Sharma has completed his Master of Research (MRes) in Molecular Oncology from Institute of Integrative Biology, University of Liverpool, UK and MSc in Biotechnology from the Department of Biotechnology, Punjabi University, India. He is currently working as an Assistant Professor at Division of Cancer Research, Department of Biotechnology, Chandigarh Group of Colleges, India. He has published papers in reputed journals and national and international conferences in UK and India. He has won a Graduate Entrepreneur Award from University of Liverpool, UK as a result of which he is developing an enterprise focused on bringing together basic elements of Ayurvedic sciences and contemporary biological sciences.

Email: biotechno16@gmail.com

Top